Mirati To Challenge EMA’s Rejection Of US-Approved Krazati
Drug Was Granted Accelerated Approval By US FDA In December 2022
Mirati Therapeutics said it disagreed with the European Medicines Agency’s decision that its lung cancer drug did not meet its conditional marketing authorization criteria.
